{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T06:11:51Z","timestamp":1758089511312,"version":"3.44.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Overactive bladder (OAB) is a common condition in women, affecting quality of life with symptoms like urgency, frequency, and nocturia. Current treatments, such as antimuscarinic drugs, have side effects that limit their effectiveness. Electroacupuncture (EA) shows promise as an alternative, but its mechanisms and effectiveness for OAB are not fully understood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This blinded, randomized controlled trial aimed to evaluate the efficacy and safety of electroacupuncture as a therapeutic intervention for female patients with OAB and to explore potential mechanisms involving the sacral and posterior tibial nerves.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sixty-eight female OAB patients were stratified and randomized into two groups. One group received EA treatment at BL33 and SP6 acupoints three times weekly for 4 weeks, while the control group received tolterodine, a standard antimuscarinic medication. Outcome measures included urgency symptoms, Overactive Bladder Symptom Score (OABSS), and quality of life at 2 and 4\u202fweeks post-treatment, as well as at a 3-month follow-up. Safety and acceptance of EA were also assessed. Additionally, urinary cytokine levels were analyzed to investigate the neurobiological impact of the treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No significant baseline differences were observed between the groups. At 2\u202fweeks, EA significantly improved quality of life scores (<jats:italic>p<\/jats:italic>\u202f=\u202f0.002), and by 4\u202fweeks, both groups showed improvements in urgency symptoms and quality of life (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.05), with no significant difference in OABSS (<jats:italic>p<\/jats:italic>\u202f=\u202f0.081). The EA group demonstrated a significantly higher overall effective rate (88.6%) compared to the medication group (48.5%) (<jats:italic>p<\/jats:italic>\u202f=\u202f0.002). Safety assessments indicated high acceptance and minimal discomfort with EA, while post-treatment urinary cytokine analysis revealed significant changes in BDNF levels, suggesting a neurobiological effect of EA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Electroacupuncture at BL33 and SP6 is a promising, well-tolerated, and effective intervention for OAB, supporting its integration into treatment paradigms. Further research is needed to optimize its clinical application.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:uri>clinicaltrials.gov<\/jats:uri>, identifier ChiCTR-1900021372.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1579276","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:36:30Z","timestamp":1758000990000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of electroacupuncture in female overactive bladder: a randomized controlled trial investigating sacral and tibial nerve modulation"],"prefix":"10.3389","volume":"12","author":[{"given":"Zilong","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengdi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junru","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"J Urol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2022.01.045","article-title":"European Association of Urology guidelines on the diagnosis and Management of Female non-neurogenic Lower Urinary Tract Symptoms. Part 1: diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence","volume":"82","author":"Nambiar","year":"2022","journal-title":"Eur Urol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s11934-013-0353-6","article-title":"Understanding clinic options for overactive bladder","volume":"14","author":"Bartley","year":"2013","journal-title":"Curr Urol Rep"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/luts.12193","article-title":"Prevalence of overactive bladder in China, Taiwan and South Korea: results from a cross-sectional, population-based study","volume":"11","author":"Chuang","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","article-title":"A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment","volume":"75","author":"Peyronnet","year":"2019","journal-title":"Eur Urol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.2147\/CIA.S252852","article-title":"Cognitive effects of anticholinergic load in women with overactive bladder","volume":"15","author":"Araklitis","year":"2020","journal-title":"Clin Interv Aging"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40266-019-00694-5","article-title":"The relationship between anticholinergic exposure and falls, fractures, and mortality in patients with overactive bladder","volume":"36","author":"Suehs","year":"2019","journal-title":"Drugs Aging"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41585-021-00504-x","article-title":"The cognitive effect of anticholinergics for patients with overactive bladder","volume":"18","author":"Welk","year":"2021","journal-title":"Nat Rev Urol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.04.010","article-title":"Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder","volume":"189","author":"Yamada","year":"2018","journal-title":"Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/luts.12304","article-title":"Current management of refractory overactive bladder","volume":"12","author":"Chen","year":"2020","journal-title":"Low Urin Tract Symptoms"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s12325-019-01205-z","article-title":"New technologies and applications in sacral neuromodulation: An update","volume":"37","author":"De Wachter","year":"2020","journal-title":"Adv Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.euf.2019.11.018","article-title":"Sacral neuromodulation: mechanism of action","volume":"6","author":"De Wachter","year":"2020","journal-title":"Eur Urol Focus"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.euf.2022.04.006","article-title":"Sacral neuromodulation using a novel device with a six-contact-point electrode for the treatment of patients with refractory overactive bladder: a multicenter, randomized, single-blind, parallel-control clinical trial","volume":"8","author":"Liao","year":"2022","journal-title":"Eur Urol Focus"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.juro.2010.10.065","article-title":"The use of bilateral sacral nerve stimulation in patients with loss of unilateral treatment efficacy","volume":"185","author":"Marcelissen","year":"2011","journal-title":"J Urol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40122-022-00405-w","article-title":"Neuromodulation in chronic pelvic pain: a narrative review","volume":"11","author":"Xiang","year":"2022","journal-title":"Pain Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/nau.23351","article-title":"The effectiveness of transcutaneous tibial nerve stimulation (TTNS) for adults with overactive bladder syndrome: a systematic review","volume":"37","author":"Booth","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.neurom.2022.04.034","article-title":"Transcutaneous Tibial nerve stimulation in the Management of Overactive Bladder: a scoping review","volume":"25","author":"Sayner","year":"2022","journal-title":"Neuromodulation"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41586-021-04001-4","article-title":"A neuroanatomical basis for electroacupuncture to drive the vagal-adrenal axis","volume":"598","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.neuron.2020.07.015","article-title":"Somatotopic organization and intensity dependence in driving distinct NPY-expressing sympathetic pathways by Electroacupuncture","volume":"108","author":"Liu","year":"2020","journal-title":"Neuron"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/j.1532-2149.2012.00145.x","article-title":"Acupuncture points are large fields: the fuzziness of acupuncture point localization by doctors in practice","volume":"16","author":"Molsberger","year":"2012","journal-title":"Eur J Pain"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"102793","DOI":"10.1016\/j.autneu.2021.102793","article-title":"Acupuncture modulates immunity in sepsis: toward a science-based protocol","volume":"232","author":"Pan","year":"2021","journal-title":"Auton Neurosci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ijsu.2011.09.004","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"9","author":"Schulz","year":"2011","journal-title":"Int J Surg"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1756-5391.2010.01086.x","article-title":"Revised STandards for reporting interventions in clinical trials of acupuncture (STRICTA): extending the CONSORT statement","volume":"3","author":"MacPherson","year":"2010","journal-title":"J Evid Based Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jval.2014.11.004","article-title":"Implications of the minimal clinically important difference for health-related quality-of-life outcomes: a comparison of sample size requirements for an incontinence treatment trial","volume":"18","author":"Halme","year":"2015","journal-title":"Value Health"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/sim.7983","article-title":"Optimal sample size planning for the Wilcoxon-Mann-Whitney test","volume":"38","author":"Happ","year":"2019","journal-title":"Stat Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1161\/01.STR.0000125010.70652.93","article-title":"Sample size calculations in acute stroke trials: a systematic review of their reporting, characteristics, and relationship with outcome","volume":"35","author":"Weaver","year":"2004","journal-title":"Stroke"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1089\/acm.2006.12.743","article-title":"The electrophysiology of de qi sensations","volume":"12","author":"Leung","year":"2006","journal-title":"J Altern Complement Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"504","DOI":"10.21037\/tau-20-1257","article-title":"Variable- versus constant-frequency sacral neuromodulation in black-zone overactive bladder patients: a study protocol for a multicenter, prospective, randomized, blind, self-controlled trial","volume":"10","author":"Meng","year":"2021","journal-title":"Transl Androl Urol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.juro.2007.03.133","article-title":"Validation of the overactive bladder symptom score","volume":"178","author":"Blaivas","year":"2007","journal-title":"J Urol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3760\/cma.j.issn.0366-6999.20131349","article-title":"Overactive bladder symptom score to evaluate efficacy of solifenacin for the treatment of overactive bladder symptoms","volume":"127","author":"Liu","year":"2014","journal-title":"Chin Med J"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"746064","DOI":"10.3389\/fmed.2022.746064","article-title":"A multi-center, randomized, blind, controlled clinical trial of the safety and efficacy of Micro radio frequency therapy system for the treatment of overactive bladder","volume":"9","author":"Xu","year":"2022","journal-title":"Front Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1001\/jama.2022.7489","article-title":"Comparison of an emoji-based visual analog scale with a numeric rating scale for pain assessment","volume":"328","author":"He","year":"2022","journal-title":"JAMA"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrn2401","article-title":"The neural control of micturition","volume":"9","author":"Fowler","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019","volume":"202","author":"Lightner","year":"2019","journal-title":"J Urol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.euf.2019.06.006","article-title":"Urinary biomarkers in overactive bladder: revisiting the evidence in 2019","volume":"5","author":"Antunes-Lopes","year":"2019","journal-title":"Eur Urol Focus"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"F28","DOI":"10.1152\/ajprenal.00580.2015","article-title":"A multiplexed analysis approach identifies new association of inflammatory proteins in patients with overactive bladder","volume":"311","author":"Ma","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/ncpuro0408","article-title":"Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders","volume":"3","author":"Steers","year":"2006","journal-title":"Nat Clin Pract Urol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3390\/biomedicines10051149","article-title":"Use of urinary cytokine and chemokine levels for identifying bladder conditions and predicting treatment outcomes in patients with interstitial cystitis\/bladder pain syndrome","volume":"10","author":"Yu","year":"2022","journal-title":"Biomedicine"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1111\/j.1464-410X.2009.08380.x","article-title":"Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder","volume":"103","author":"Liu","year":"2009","journal-title":"BJU Int"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.neuroscience.2010.01.015","article-title":"Sequestration of brain derived nerve factor by intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis","volume":"166","author":"Pinto","year":"2010","journal-title":"Neuroscience"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrurol.2014.244","article-title":"Brain-derived neurotrophic factor in urinary continence and incontinence","volume":"11","author":"Song","year":"2014","journal-title":"Nat Rev Urol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1016\/j.juro.2007.06.044","article-title":"Antimuscarinic drug inhibits detrusor overactivity induced by topical application of prostaglandin E2 to the urethra with a decrease in urethral pressure","volume":"178","author":"Yokoyama","year":"2007","journal-title":"J Urol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s11255-009-9647-5","article-title":"Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study","volume":"42","author":"Tyagi","year":"2010","journal-title":"Int Urol Nephrol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/ijcp.12317","article-title":"Urgency and pain in patients with overactive bladder and bladder pain syndrome. What are the differences?","volume":"68","author":"Castro-Diaz","year":"2014","journal-title":"Int J Clin Pract"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4293\/108680810X12674612014743","article-title":"The overlap of interstitial cystitis\/painful bladder syndrome and overactive bladder","volume":"14","author":"Chung","year":"2010","journal-title":"JSLS"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3389\/fnins.2018.00931","article-title":"Mechanisms underlying overactive bladder and interstitial cystitis\/painful bladder syndrome","volume":"12","author":"Grundy","year":"2018","journal-title":"Front Neurosci"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.eururo.2008.02.037","article-title":"Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type a for the treatment of neurogenic or idiopathic detrusor overactivity","volume":"53","author":"Apostolidis","year":"2008","journal-title":"Eur Urol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"12044","DOI":"10.3390\/ijms231912044","article-title":"Usefulness of urinary biomarkers for assessing bladder condition and histopathology in patients with interstitial cystitis\/bladder pain syndrome","volume":"23","author":"Jiang","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1579276\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:36:32Z","timestamp":1758000992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1579276\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":48,"alternative-id":["10.3389\/fmed.2025.1579276"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1579276","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"article-number":"1579276"}}